African isolates show a high proportion of multiple copies of
                the Plasmodium falciparum plasmepsin-2 gene, a piperaquine
                resistance marker by Leroy, Didier et al.
Leroy et al. Malar J          (2019) 18:126  
https://doi.org/10.1186/s12936-019-2756-4
RESEARCH
African isolates show a high proportion 
of multiple copies of the Plasmodium falciparum 
plasmepsin-2 gene, a piperaquine resistance 
marker
Didier Leroy1* , Fiona Macintyre1, Yeka Adoke2, Serge Ouoba3, Aissata Barry3, Ghyslain Mombo‑Ngoma4,5, 
Jacques Mari Ndong Ngomo6, Rosauro Varo7,8,9, Yannelle Dossou10, Antoinette Kitoto Tshefu11, 
Tran Thanh Duong12, Bui Quang Phuc13, Bart Laurijssens14, Roland Klopper15, Nimol Khim16, Eric Legrand17 
and Didier Ménard17*
Abstract 
Background: Today, the development of new and well‑tolerated anti‑malarial drugs is strongly justified by the emer‑
gence of Plasmodium falciparum resistance. In 2014–2015, a phase 2b clinical study was conducted to evaluate the 
efficacy of a single oral dose of Artefenomel (OZ439)–piperaquine (PPQ) in Asian and African patients presenting with 
uncomplicated falciparum malaria.
Methods: Blood samples collected before treatment offered the opportunity to investigate the proportion of mul‑
tidrug resistant parasite genotypes, including P. falciparum kelch13 mutations and copy number variation of both P. 
falciparum plasmepsin 2 (Pfpm2) and P. falciparum multidrug resistance 1 (Pfmdr1) genes.
Results: Validated kelch13 resistance mutations including C580Y, I543T, P553L and V568G were only detected in 
parasites from Vietnamese patients. In Africa, isolates with multiple copies of the Pfmdr1 gene were shown to be more 
frequent than previously reported (21.1%, range from 12.4% in Burkina Faso to 27.4% in Uganda). More strikingly, high 
proportions of isolates with multiple copies of the Pfpm2 gene, associated with piperaquine (PPQ) resistance, were 
frequently observed in the African sites, especially in Burkina Faso and Uganda (> 30%).
Conclusions: These findings were considered to sharply contrast with the recent description of increased sensitivity 
to PPQ of Ugandan parasite isolates. This emphasizes the necessity to investigate in vitro susceptibility profiles to PPQ 
of African isolates with multiple copies of the Pfpm2 gene and estimate the risk of development of PPQ resistance in 
Africa.
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Background
Emergence of Plasmodium falciparum resistance to anti-
malarial drugs is currently the primary rationale support-
ing the development of new and well-tolerated drugs. 
While the estimated number of malaria cases in the 
world decreased from 237 million (218–278 million) in 
2010, to 211 million (192–257 million) in 2015, the mor-
bidity and the mortality have stabilized in 2016 with esti-
mates of 216 million cases (196–263 million) and 445,000 
deaths (compared to 446,000 in 2015) as reported by the 
World Health Organization (WHO) [1–3].
Globally, the vast majority of deaths (> 90%) caused 
by malaria is due to P. falciparum infections, occurring 
in Africa, in children under 5 years of age. Artemisinin-
based combination therapy (ACT) which are currently 
recommended as first-line treatment of uncomplicated 
falciparum malaria, is less effective in Southeast Asia, 
particularly in Cambodia, where high rates of treatment 
failure associated with artemisinin and piperaquine 
resistance are currently reported [4–16]. The contain-
ment and the elimination of these multidrug resistant 
parasites in Southeast Asia are a priority for the WHO 
to avoid their spread to Africa as was the case with previ-
ous generations of anti-malarial drugs (e.g. chloroquine, 
sulfadoxine–pyrimethamine) [17]. Fortunately, molecu-
lar markers associated with such resistance are available 
[10]. In particular, mutations in the propeller domain of a 
kelch gene located on the chromosome 13 (kelch13), and 
amplification of a cluster of genes encoding both plas-
mepsin 2 (Pfpm2) and plasmepsin 3 proteins, have been 
recently shown to be associated with artemisinin and 
PPQ resistance, respectively [18–20].
According to the latest WHO update on artemisinin 
resistance [21], to be validated a kelch13 resistance 
mutant has to be correlated with delayed parasite clear-
ance in clinical studies and reduced drug in  vitro sus-
ceptibility with survival rate ≥ 1% expressed by the 
Ring-stage Survival Assay, (RSA0–3  h) in fresh isolates 
(ex vivo assays), or culture-adapted field parasites or 
kelch13 genome-edited parasites (in vitro assays) [22–25]. 
To date, only nine kelch13 mutations have been shown 
to be validated (C580Y, Y493H, R539T, I543T, N458Y, 
P533L, M476I, R561H and F446I). The F446I mutant is 
highly prevalent in Myanmar as recently reported [26]. In 
Africa, a broad array of rare non-synonymous mutations 
in the kelch13 gene have been described in P. falciparum 
isolates, but none of these mutants have been associated 
with artemisinin resistance [27], attesting that not all 
non-synonymous kelch13 mutations confer resistance to 
artemisinin.
More recently, resistance to PPQ has been associated 
with an increase of survival rates of parasite exposed to 
200  nM PPQ for 48  h in the piperaquine survival assay 
(PSA) and with the amplification of plasmepsin 2–3 
genes (Pfpm2–3) [6, 20]. In Cambodia, where high rates 
of treatment failure to dihydroartemisinin–piperaquine 
(DHA–PPQ) are observed (i.e. > 60% in some provinces), 
it has been demonstrated that amplification of Pfpm2 
gene and presence of validated kelch13 mutations were 
highly predictive of DHA–PPQ treatment failure [20]. 
Most of these parasites harbour a single copy of Pfmdr1 
gene leading to the recovery of mefloquine sensitivity 
[4, 6] and suggesting a natural antagonism between PPQ 
resistance and mefloquine resistance. However, so far it 
was not understood whether Pfmdr1 de-amplification 
(from multiple copies to single copy Pfmdr1) was due 
to the implementation of DHA–PPQ as first-line treat-
ment or due to the release of mefloquine pressure and 
an increase in parasite fitness accompanying Pfmdr1 
gene de-amplification. To date, DHA–PPQ resistance 
was confined to Southeast Asia. So far, only few studies 
conducted on parasites from Mozambique and Mali have 
provided evidence of the presence (at low frequency, 
1.1%, 10%) of parasites carrying multiple copies of Pfpm2 
[28, 29].
Facing the threat of losing all current artemisinin-based 
combinations front-line therapies due to resistance, a 
new generation of endoperoxides with more favourable 
pharmacokinetic profiles like the ozonide  Artefenomel® 
(OZ439) have been developed [30]. The efficacy of this 
new chemical entity was evaluated in combination with 
PPQ in African and Southeast Asian (Vietnam) patients 
with uncomplicated falciparum malaria infection [30]. 
The primary objective of this phase 2b clinical study was 
to determine whether a single oral dose combination 
of artefenomel/PPQ was efficacious and safe [≥ 95% of 
patients cured on the basis of polymerase chain reaction 
(PCR)-adjusted adequate clinical parasitological response 
at day 28 (ACPR28)] in adults and children infected by P. 
falciparum. Blood samples collected in 2014–2015 from 
this clinical trial offered the opportunity to investigate 
the proportion of multidrug resistant parasites (i.e. P. fal-
ciparum kelch13 mutants and gene copy number of both 
Pfpm2 and Pfmdr1). Here, the occurrence of such geno-
types from these samples is reported and a map of poten-
tial risk of emergence of resistance to the main front-line 
therapies currently used to treat malaria-infected patients 
and to the next generation of anti-malarial combinations 
is provided.
Methods
Study design, study sites and population
The study was a randomized, double-blind, single-dose 
design to investigate the efficacy, safety, tolerability and 
pharmacokinetics of artefenomel 800  mg in loose com-
bination with three doses of PPQ phosphate (640  mg, 
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960  mg, 1440  mg) in male and female patients aged 
≥ 6  months to < 70  years, with uncomplicated falcipa-
rum malaria in Africa and Southeast Asia (Vietnam), as 
previously described [31]. This study was conducted in 
13 sites, including Burkina Faso (three sites, N = 127), 
Uganda (one site, N = 124), Benin (one site, N = 1), the 
Democratic Republic of Congo (one site, N = 5), Gabon 
(two sites, N = 94), Mozambique (one site, N = 14), and 
Vietnam (four sites, N = 83). A total of 448 patients were 
randomized into each of three treatment arms: arte-
fenomel 800  mg/PPQ 640  mg (N = 148), artefenomel 
800 mg/PPQ 960 mg (N = 151) and artefenomel 800 mg/
PPQ 1440  mg (N = 149). Patients presenting P. falcipa-
rum mono-infection confirmed by microscopy to be 
in the range of 1000 to 100,000 asexual parasites/μL of 
blood, and with fever (axillary temperature ≥ 37.5  °C) 
or reported fever episodes in the preceding 24  h, were 
included in the study after having submitted their written 
informed consent/assent. The following important exclu-
sion criteria were considered: presence of severe malaria 
(WHO definition), haemoglobin below 8  g/dL, known 
history or evidence of clinically significant cardiac disor-
der, including QTcF or QTc B > 450 ms, or family history 
of sudden death or clinical conditions known to prolong 
QTc, clinically significant hepatic dysfunction and prior 
anti-malarial treatment within a specified time windows. 
After the drugs administration, patients were followed 
for 42 days or 63 days at some centres. Patients remained 
in the clinical unit for a minimum of 48  h (African 
patients > 5 years old) or 72 h (African patients ≤ 5 years 
old and all Asian patients) and were discharged on the 
basis of absence of detectable parasites and fever.
DNA extraction
Plasmodium falciparum DNA was extracted from dried 
blood spots using the QIAamp DNA Mini kit (Qiagen, 
Germany), according to the manufacturer’s instructions. 
Samples were screened to confirm the presence of P. 
falciparum DNA using first a qualitative real-time PCR 
assay targeting the Plasmodium cytochrome b gene and 
secondly on positive samples, four real-time PCR assays 
specifically amplifying P. falciparum, Plasmodium vivax, 
Plasmodium ovale and Plasmodium malariae [32].
Detection of kelch13 mutations
Plasmodium falciparum positive samples were tested 
for the presence of mutations in the propeller domain of 
the kelch13 gene (PF3D7_1343700) that have been asso-
ciated with artemisinin resistance [19]. Amplification of 
the Kelch-propeller domain (codons 440–680, 720  bp) 
was performed as previously described [27]. Cross-con-
tamination was evaluated by adding no template sam-
ples (dried blood spots negative for P. falciparum) in 
each PCR run. PCR products were sequenced by Mac-
rogen (Seoul, Korea). Electropherograms were analysed 
on both strands, using PF3D7_1343700 as the reference 
sequence. The quality of the procedure was assessed by 
including dried blood spots with known kelch13 muta-
tions (wild-type, C580Y, R539T, I543T, Y493H) which 
were tested blindly in the same batches (each 96-well) 
with the test samples. Isolates with mixed alleles were 
considered as mutant. Following WHO recommenda-
tions, kelch13 mutants were classified in three groups: (i) 
wild-type group (parasites with no synonymous or non-
synonymous mutations compared to 3D7 sequence), (ii) 
kelch13 validated (F446I, N458Y, M476I, Y493H, R539T, 
I543T, P553L, R561H, C580Y) and candidate mutation 
(P441L, G339A, V568G, P574L, A675V) group, and (iii) 
other kelch13 mutants group (parasites with synonymous 
or non-synonymous mutations not present in the kelch13 
validated and candidate resistance mutation group).
Pfpm2 and Pfmdr1 gene copy number variation assessment
Pfpm2 (PF3D7_1408000) and Pfmdr1 (PF3D7_0523000) 
gene copy number were measured by qPCR using a 
CFX96 real-time PCR machine (Bio-Rad, France), rela-
tive to the single copy of the β-tubulin gene (used as ref-
erence gene), as previously described [20]. Amplification 
was carried out in triplicate. In each amplification run, 
six replicates using DNA from 3D7 parasite reference 
clone and three replicates without template (water) used 
as negative controls were included. Copy numbers were 
calculated using the formula: copy number = 2−ΔΔCt; 
with ΔΔCt denoting the difference between ΔCt of the 
unknown sample and ΔCt of the reference sample (3D7). 
Specificities of Pfpm2 and Pfmdr1 amplification curves 
were evaluated by visualizing the melt curves. Multiple 
copies vs single copy, of both Pfmdr1 and PfPm2, were 
defined as copy numbers < 1.5 and ≥ 1.5 respectively.
Statistical analysis
Data were recorded and analyzed using Excel software 
and MedCalc (MedCalc Software, Belgium). Groups 
were compared using the Chi squared test or the Fisher’s 
exact test. All reported P-values are two-sided and were 
considered statistically significant if < 0.05.
Results
The P. falciparum samples collected from patients before 
treatment and yielding a successful result, by country and 
molecular assay, are presented in Table 1.
Global genotypes overview
Among the 68 Southeast Asian clinical isolates collected 
in Vietnam with available data, 67.6% (46/68) were found 
to harbour parasites with validated or candidate kelch13 
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resistance mutations (Table 2). Details regarding kelch13 
mutants according to the collection sites are presented 
in Table  3. By contrast, none of the 332 isolates col-
lected from African patients and successfully tested were 
found to carry validated or candidate kelch13 resistance 
mutations.
Significant difference in proportion of isolates with 
multiple copies Pfmdr1 were found between Africa 
(21.1%, 64/304, 95% CI 16.2–26.9%) and Asia (6.3%, 5/79, 
95% CI 2.0–14.8%, P = 0.002, Table  2). Parasites with 
multiple copies of Pfpm2 were observed in 11 Asian sam-
ples (13.9%, 11/79, 95% CI 6.9–24.9%) and unexpectedly 
at higher proportion in African isolates (26.8%, 80/298, 
95% CI 21.3–33.4%, P = 0.02, Table  2). However, multi-
ple copies of Pfpm2/single copy Pfmdr1, hypothesized 
to favour resistance to PPQ, were found at similar pro-
portion in a small cohort of 10 Asian isolates (12.7%, 
10/79, 95% CI 6.1–23.3%) and 47 African samples (15.8%, 
47/298, 95% CI 11.6–21.0%, P = 0.72, Table 2 and Fig. 1).
In Asia, seven isolates (10.8%, 7/65, 95% CI 4.3–22.2%) 
had genotypes associated with both artemisinin and 
PPQ resistance (i.e. with kelch13 validated and candidate 
resistance mutations, and multiple copy Pfpm2/single 
copy Pfmdr1) (Fig. 2a). In Africa, no clinical isolates had 
mutations conferring both artemisinin and PPQ resist-
ance due to the absence of kelch13 mutant-type parasites 
(Fig. 2b).
Southeast Asian (Vietnamese) genotypes
kelch13 validated and candidate mutations were detected 
in > 60% of the isolates in all sites (from 61.1% in Gai Lai 
to 73.0% in Binh Phuoc) except Quang Tri (where only 
one sample was collected) (Table 3). C580Y was the most 
predominant kelch13 validated and candidate mutation 
Table 1 Number of  isolates collected from  each site 
in  Southeast Asia (Vietnam) and  Africa and  number 
and proportion of successful molecular tests
Sites No. isolates No. of successful tests (%)
kelch 13 Pfpm2 Pfmdr1
Southeast Asia
 Gai Lai 18 13 (72) 18 (100) 18 (100)
 Binh Phuoc 30 26 (87) 28 (93) 28 (93)
 Quang Tri 1 1 (100) 1 (100) 1 (100)
 Khanh Hao 34 28 (82) 32 (94) 32 (94)
Africa
 Benin 1 1 (100) 0 (0) 0 (0)
 Burkina Faso 127 114 (90) 105 (83) 105 (83)
 DR Congo 5 4 (80) 2 (40) 2 (40)
 Gabon 94 83 (88) 71 (76) 72 (77)
 Mozambique 14 14 (100) 8 (57) 12 (86)
 Uganda 124 116 (94) 112 (90) 113 (91)
Total 448 400 (89) 377 (84) 383 (85)
Table 2 Distribution (number and proportion) of genotypes (kelch13 mutations, Pfmdr1 and Pfpm2 gene copy numbers) 
detected in Plasmodium falciparum isolates collected from Southeast Asia and Africa in 2014–2015
ART: validated or candidate kelch 13 mutations; WT: kelch 13 Wild type, OTH: kelch 13 mutations with unknown association with artemisinin resistance (detailed in 
Tables 3 and 4)
Italic font denotes the allele or haplotype associate with drug resistance. P-value (Chi squared  test± or Fischer exact  test¥)
Locus Allele/haplotype Number of isolates (%) detected in P value
Asia (N = 82) Africa (N = 355)
kelch 13 ART 46 (67.6) 0 (0.0) < 10−4±
OTH 1 (1.5) 10 (3.0)
WT 21 (30.9) 322 (97.0)
Pfpm2 Single copy 68 (86.1) 218 (73.2) 0.02¥
Multiple copies 11 (13.9) 80 (26.8)
Pfmdr1 Single copy 74 (93.7) 240 (78.9) 0.002¥
Multiple copies 5 (6.3) 64 (21.1)
Pfpm2/Pfmdr1 Single copy/single copy 64 (81.0) 189 (63.4) 0.009±
Single copy/multiple copies 4 (5.1) 29 (9.7)
Multiple copies/single copy 10 (12.7) 47 (15.8)
Multiple copies/multiple copies 1 (1.3) 33 (11.1)
kelch 13/Pfpm2/Pfmdr1 ART/multiple copies/single copy 7 (10.8) 0 (0.0) < 10−4±
WT/multiple copies/single copy 2 (3.0) 43 (14.7)
ART/others 38 (57.5) 0 (0.0)
WT/others 18 (27.3) 241 (82.5)
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(54.3%, 25/46, 95% CI 25.2–80.2%) followed by P553L 
(37.0%, 17/46, 95% CI 21.5–59.2%), I543T (2.2%, 1/46, 
95% CI 0.5–12.1%) and G568G (2.2%, 1/46, 95% CI 0.5–
12.1%). In Khanh Hao, two isolates were found to have 
both C580Y and P553L single mutant parasites (likely 
from a polyclonal infection).
Isolates with multiple copies of Pfpm2 were detected 
only in two sites located along the Cambodian border: 
in Gai Lai (16.7%, 3/18, 95% CI 3.4–48.7%) and in Binh 
Phuoc (28.6%, 8/28, 95% CI 12.3–56.3%). No parasites 
with multiple copies were detected out of 32 isolates in 
Khanh Hao. Parasites with a single copy of Pfmdr1 were 
frequent (> 88%) in samples collected from all four study 
sites (from 88.9% in Gai Lai to 100% in Quang Tri).
Parasites with multiple copies Pfpm2/single copy 
Pfmdr1 were observed in 10/79 (12.7%, 95% CI 6.1–
23.3%) of the isolates collected from Vietnamese patients, 
representing in Gai Lai 11.1% (2/18, 95% CI 1.4–40.1%) 
and in Binh Phuoc 28.6% (8/28, 95% CI 12.3–56.3%).
Isolates with genotype conferring both artemisinin and 
PPQ resistance (i.e. with kelch13 validated and candidate 
mutations, and multiple copy Pfpm2/single copy Pfmdr1) 
Table 3 Distribution (number and proportion) of genotypes (kelch13 mutations, Pfmdr1 and Pfpm2 gene copy numbers) 
detected in Plasmodium falciparum isolates collected in four sites located in Southeast Asia in 2014–2015
ART: validated or candidate kelch 13 mutations; WT: kelch 13 Wild type, OTH: kelch 13 mutations with unknown association with artemisinin resistance
Italic font denotes the allele or haplotype associate with drug resistance
Locus Allele/haplotype Site
Gai Lai Binh Phuoc Quang Tri Khanh Hao
N % N % N % N %
kelch 13 ART 
 C580Y 3 23.1 16 61.5 0 6 21.4
 C580Y + P553L 0 0 0 2 7.1
 I543T 0 1 3.8 0 0
 P553L 4 30.8 2 7.7 0 11 39.3
 V568G 1 7.7 0 0 0
OTH C469P 1 7.7 0 0 0
WT 4 30.8 7 26.9 1 100 9 32.1
Pfpm2 Single copy 15 83.3 20 71.4 1 100 32 100
Multiple copies 3 16.7 8 28.6 0 0
Pfmdr1 Single copy 16 88.9 27 96.4 1 100 30 93.8
Multiple copies 2 11.1 1 3.6 0 2 6.3
Pfpm2/Pfmdr1 Single copy/single copy 14 77.8 19 67.9 1 100 30 93.8
Single copy/multiple copies 1 5.6 1 3.6 0 2 6.3
Multiple copies/single copy 2 11.1 8 28.6 0 0
Multiple copies/multiple copies 1 5.6 0 0 0
kelch 13/Pfpm2/Pfmdr1 ART 
 Single copy/single copy 7 53.8 10 41.7 0 18 64.3
 Single copy/multiple copies 0 1 4.2 0 1 3.6
 Multiple copies/single copy 0 7 29.2 0 0
 Multiple copies/multiple copies 1 7.7 0 – 0 0
OTH
 Single copy/single copy – 0 0 0
 Single copy/multiple copies 1 7.7 0 0 0
 Multiple copies/single copy – 0 0 0
 Multiple copies/multiple copies – 0 0 0
WT
 Single copy/single copy 2 15.4 6 25 1 100 8 28.6
 Single copy/multiple copies – 0 0 1 3.6
 Multiple copies/single copy 2 15.4 0 0 0
 Multiple copies/multiple copies – 0 0 0
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were only observed in patients enrolled in Binh Phuoc 
(29.2%, 7/24, 95% CI 11.7–60.0%).
African genotypes
No kelch13 validated and candidate mutations was 
detected at any site. Other non-synonymous mutations 
were observed: A578S was the most predominant kelch13 
mutation (7/10; 3 in Uganda, 2 in Gabon, 1 in Mozam-
bique and 1 in Burkina Faso) followed by Y541F, M562T 
and A626V (only detected once in isolates from Burkina 
Faso) (Table 4).
Isolates from Uganda and Burkina Faso showed an 
unexpected high frequency of parasites with multiple 
copies of Pfpm2 (33.9%, 38/112, 95% CI 24.0–46.6% and 
30.5%, 32/105, 95% CI 20.9–43.0%, respectively). Samples 
from Gabon and Mozambique had a lower frequency 
of multiple copies of Pfpm2 estimated at 11.3% (8/71, 
95% CI 4.9–22.2%) and 12.5% (1/8, 95% CI 0.3–69.6%), 
respectively. Of note, in the Democratic Republic of 
Congo, results from two isolates were available and one 
isolate was found to carry parasites with multiple copies 
of Pfpm2.
Parasites with single copy Pfmdr1 were detected in 
almost all isolates in patients enrolled across the six 
African sites, therefore, only 13/105 (12.4%, 95% CI 
6.6–21.2%) isolates from Burkina Faso, 2/12 (16.7%, 
95% CI 2.0–60.2%) from Mozambique, 17/72 (23.6%, 
95% CI 13.8–37.8%) from Gabon and 31/113 (27.4%, 
95% CI 18.6–38.9%) from Uganda had multiple copies 
of Pfmdr1. One out of two patients harboured para-
sites with multiple copies of Pfmdr1 in DRC.
Parasites with multiple copies Pfpm2/single copy 
Pfmdr1 were observed at a frequency of 20.9% (22/105, 
95% CI 13.1–31.7%) in Burkina Faso, 18.8% (21/112, 
95% CI 11.6–28.7%) in Uganda, 12.5% (1/8, 95% CI 
0.3–69.7%) in Mozambique and 4.3% (3/71, 95% CI 
0.9–12.5%) in Gabon. However, isolates with genotype 
conferring both artemisinin and PPQ resistance (i.e. 
with kelch13 validated and candidate mutations, and 
multiple copy Pfpm2/single copy Pfmdr1) were not 
observed in patients enrolled in Africa since there were 
no kelch13 validated and candidate mutations.
Fig. 1 Pfmdr1 and Pfpm2 gene copy numbers of Plasmodium falciparum isolates collected from Southeast Asia (in red) and from Africa (in black). 
Proportion of the isolates from Southeast Asia and African are given for each group: Pfpm2 single copy/Pfmdr1 single copy (lower‑left quadrant), 
Pfpm2 single copy/Pfmdr1 multiple copies (upper‑left), Pfpm2 multiple copies/Pfmdr1 single copy (lower‑right) and Pfpm2 multiple copies/Pfmdr1 
multiple copies (upper‑right)
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Discussion
The current phase 2b clinical study of artefenomel, 
an ozonide showing improved pharmacokinetics 
properties compared to artemisinins, combined with 
PPQ was designed to assess the efficacy of single oral 
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Fig. 2 Kelch13 mutations, Pfmdr1 and Pfpm2 gene copy numbers of Plasmodium falciparum isolates collected from four sites in Southeast Asia (a) 
and from nine sites in Africa (b). Each of the kelch13 mutations are presented with different symbols and colours. Open triangle represents isolates 
with unavailable kelch13 data. The four quadrants in both panels present isolates with Pfpm2 single copy/Pfmdr1 single copy (lower‑left quandrant), 
Pfpm2 single copy/Pfmdr1 multiple copies (upper‑left), Pfpm2 multiple copies/Pfmdr1 single copy (lower‑right) and Pfpm2 multiple copies/Pfmdr1 
multiple copies (upper‑right)
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malaria in Southeast Asia (Vietnam) and Africa. In 
addition to the clinical outcome assessment, three 
molecular markers associated with drug resistance for 
mapping the potential risks of future treatment failures 
were investigated in isolates collected before treatment. 
The frequency of kKelch13 mutations associated with 
artemisinin resistance, and Pfmdr1 and Pfpm2 genes 
copy number were measured in available isolates col-
lected from all clinical sites. Artemisinin resistance was 
confirmed to be still confined in Southeast Asia. A high 
proportion of kelch13 validated and candidate resist-
ance mutations were observed as well as a new unre-
ported one (C469P) in Vietnamese parasites and the 
complete absence of these mutants in African isolates. 
As previously reported [27, 33, 34], a low proportion of 
kelch13 mutations was detected in African samples and 
all these mutations have not been shown to be associ-
ated to artemisinin resistance [27].
However, a higher proportion (threefold) of parasites 
with multiple copies of Pfmdr1, a gene encoding a drug 
Table 4 Distribution (number and proportion) of genotypes (kelch13 mutations, Pfmdr1 and Pfpm2 gene copy numbers) 
detected in Plasmodium falciparum isolates collected in nine sites located in Africa in 2014–2015
Countries: BEN: Benin; BF: Burkina Faso; DRC: Democratic Republic of Congo; GAB: Gabon; MOZ: Mozambique; UGA: Uganda. ART: validated or candidate kelch13 
mutations; WT: kelch 13 Wild type, OTH: kelch13 mutations with unknown association with artemisinin resistance
Italic font denotes the allele or haplotype associate with drug resistance
Locus Allele/haplotype Site
BEN BF DRC GAB MOZ UGA 
N % N % N % N % N % N %
kelch 13 ART 0 0 0 0 0 0
OTH
 A578S 0 1 0.875 0 2 2.4 1 7.1 3 2.6
 Y541F 0 1 0.875 0 0 0 0
 M562T 0 1 0.875 0 0 0 0
 A626V 0 1 0.875 0 0 0 0
WT 1 100 110 96.5 4 100 81 97.6 13 92.9 113 97.4
Pfpm2 Single copy 0 73 69.5 1 50 63 88.7 7 87.5 74 66.1
Multiple copies 0 32 30.5 1 50 8 11.3 1 12.5 38 33.9
Pfmdr1 Single copy 0 92 87.6 1 50 55 76.4 10 83.3 82 72.6
Multiple copies 0 13 12.4 1 50 17 23.6 2 16.7 31 27.4
Pfpm2/Pfmdr1 Single copy/single copy 0 70 66.7 1 50 51 71.8 7 87.5 60 53.6
Single copy/multiple copies 0 3 2.9 0 12 16.9 0 14 12.5
Multiple copies/single copy 0 22 20.9 0 3 4.3 1 12.5 21 18.8
Multiple copies/multiple copies 0 10 9.4 1 50 5 7 0 17 15.1
kelch 13/Pfpm2/Pfmdr1 ART 
 Single copy/single copy 0 0 0 0 0
 Single copy/multiple copies 0 0 0 0 0
 Multiple copies/single copy 0 0 0 0 0
 Multiple copies/multiple copies 0 0 0 0 0
OTH
 Single copy/single copy 0 0 0 0 1 12.5 2 1.9
 Single copy/multiple copies 0 1 1 0 1 1.5 0 1 0.9
 Multiple copies/single copy 0 2 1.9 0 0 0
 Multiple copies/multiple copies 0 0 0 0 0
WT
 Single copy/single copy 0 69 66.3 1 50 51 71.8 6 75 56 52.3
 Single copy/multiple copies 0 3 2.9 0 11 15.5 0 13 12.1
 Multiple copies/single copy 0 20 19.2 0 3 4.2 1 12.5 19 17.8
 Multiple copies/multiple copies 0 9 8.7 1 50 5 7 0 16 15
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efflux pump, was observed in African samples com-
pared to Southeast Asian isolates. This observation con-
trasts with previous reports showing high frequency of 
parasites with multiple copies of Pfmdr1 in Asia [35–37] 
compared to Africa [38–40]. These finding likely reflect 
the profiles of evolution of P. falciparum populations 
linked to anti-malarial drug pressure in both continents. 
Especially, the prevalence of high Pfmdr1 amplification 
observed in Africa might be linked with the routine use of 
artemether–lumefantrine as first-line treatment for more 
than a decade. Indeed, increased pfmdr1 copy number is 
known to modulate parasite responses to a wide range 
of drugs including lumefantrine [38, 41, 42]. Support-
ing this expectation, it seems feasible that such parasites 
exposed to lumefantrine as monotherapy for several days 
following clearance of artemether have been selected, 
while parasites with a single copy have been eliminated. 
In contrast, the low prevalence of Pfmdr1 multiple cop-
ies observed in Southeast Asia could be due to the recent 
implementation of DHA–PPQ, the removal of the meflo-
quine drug pressure or both, as the case in Cambodia 
[18, 20, 43]. Resistance to piperaquine and resistance to 
mefloquine have been shown to be mutually exclusive in 
South East Asia. A possible inverse susceptibility mecha-
nism could be at the origin of this observation.
High frequency of isolates with multiple copies of the 
Pfpm2 has already been reported in recent studies con-
ducted in Cambodia [18, 20, 43]. As the Vietnamese 
clinical sites (Gai Lai and Binh Phuoc) are located along-
side the Cambodian border (Fig. 2), data from this study 
might reflect an evolving situation where the ampli-
fication of Pfpm2 is spreading beyond Cambodia, as 
described recently [5, 7]. To date, frequencies observed 
in Vietnamese isolates are not yet as high as the ones 
observed in Cambodia but might continue to increase in 
the future.
Unexpectedly, in African isolates, amplification of 
Pfpm2 gene was shown to occur at a much higher fre-
quency (~ 27% on average across clinical sites in Africa, 
reaching 30.5% in Burkina Faso and 33.9% in Uganda) 
than was recently described (from 11.1 to 13.8% in 
Uganda, 10% in Mali and 1.1% in Mozambique) [28, 29, 
44]. Considering the geographical extent and the diversity 
of the clinical sites in Africa, the high frequency reported 
at sites distant to each other suggests that amplification 
of Pfpm2 gene occurred independently in each site. More 
importantly, since in Southeast Asia most parasites with 
multiple copies of Pfpm2 also display kelch13 resistance 
mutations, which is not the case in African samples, it is 
likely that Pfpm2 amplification originated in Africa, inde-
pendently of Southeast Asia.
Unfortunately, in  vitro or ex  vivo drug susceptibil-
ity assays were not possible and association between 
Pfpm2 amplification and clinical resistance to PPQ was 
not verifiable in the current study. An evaluation is cur-
rently ongoing to see whether, and if so to what extent, 
these markers of artemisinin and PPQ resistance affected 
the parasite clearance half-life (PCT1/2) and PCR-
adjusted 28 days follow-up in patients treated with arte-
fenomel/PPQ (study MMV OZ439 13,003). However, it 
was recently reported that compared to drug sensitivities 
measured on Ugandan isolates from 2010 to 2013 (from 
the same site, namely Tororo), those measured in 2016 
to chloroquine, amodiaquine, and PPQ were increased 
by 7.4, 5.2 and 2.5-fold, respectively [44]. This longitudi-
nal study showed that rather than drug resistance devel-
oping to these three anti-malarial drugs, an increase in 
sensitivity was observed that was correlated with low 
prevalence of the polymorphisms recently associated 
with resistance to artemisinins or PPQ. Indeed, clini-
cal resistance to DHA-PPQ has not yet been reported in 
Africa [45]. Although, the possibility that parasites show-
ing amplification of Pfpm2 observed in the current study 
are resistant to PPQ without confirmation of in vitro or 
ex  vivo phenotypes cannot be excluded, data reported 
by Rasmussen et  al. [44] suggest that significant occur-
rence of clinical resistance to PPQ is unlikely. In other 
words, in Africa it is unclear whether the amplification of 
Pfpm2 is necessary and/or sufficient for the development 
of resistance to PPQ. The ongoing analysis relating the 
markers of resistance to clinical outcome may provide 
some insights regarding this question. Until very recently, 
it was still debated whether additional genetic modifica-
tions in the P. falciparum chloroquine resistance trans-
porter (Pfcrt) gene are required to confer such resistance 
[46, 47]. Recent genomic and biological investigations 
have revealed a rapid increase in the prevalence of novel 
Pfcrt mutations in Cambodia (H97Y, F145I, M343L, and 
G353V). These mutants (from culture-adapted Cambo-
dian field isolates or Dd2 gene-edited clones) were con-
firmed to confer PPQ resistance as determined using the 
 PSA0–3h [6, 48].
Conclusions
At present, several artemisinin-based combinations are 
used in Africa and Asia to treat patients with uncom-
plicated malaria. Artemether–lumefantrine (AL), 
artesunate–amodiaquine (AS–AQ), artesunate–meflo-
quine (AS–MQ), artesunate–sulfadoxine–pyrimeth-
amine (AS–SP), dihydroartemisinin–piperaquine 
(DHA–PPQ) and pyronaridine–artesunate (PA) 
achieve more than 95% efficacy in clinical trials based 
on PCR-adjusted Day 28 ACPR. Due to the long post 
treatment prophylaxis of the well-tolerated PPQ, 
DHA–PPQ is currently under evaluation in a number 
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of interventions, such as intermittent preventive treat-
ment in pregnant women or in infants (IPTp, IPTi) and 
mass drug administration campaigns (MDA) in Africa. 
As a key surveillance goal, it is therefore of particu-
lar importance to continue following the evolution of 
Pfpm2 amplification along with mutations in the Pfcrt 
gene and to investigate whether these genetic signa-
tures are associated with PPQ resistance in Africa.
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